Daily Cardiology Research Analysis
Three high-impact cardiology studies stood out today: a large Lancet meta-analysis quantifying blood pressure–lowering efficacy across antihypertensive monotherapies and combinations; a JAMA Cardiology randomized trial confirming 3-year benefits of physiology-guided complete revascularization in older MI patients; and a JACC randomized trial showing routine CCTA after left main PCI did not change composite outcomes but reduced spontaneous MI while increasing imaging-triggered revascularization.
Summary
Three high-impact cardiology studies stood out today: a large Lancet meta-analysis quantifying blood pressure–lowering efficacy across antihypertensive monotherapies and combinations; a JAMA Cardiology randomized trial confirming 3-year benefits of physiology-guided complete revascularization in older MI patients; and a JACC randomized trial showing routine CCTA after left main PCI did not change composite outcomes but reduced spontaneous MI while increasing imaging-triggered revascularization.
Research Themes
- Quantitative optimization of antihypertensive therapy and combinations
- Long-term benefits of physiology-guided complete revascularization in elderly MI
- Value and trade-offs of routine CCTA surveillance after left main PCI
Selected Articles
1. Blood pressure-lowering efficacy of antihypertensive drugs and their combinations: a systematic review and meta-analysis of randomised, double-blind, placebo-controlled trials.
Across 484 randomized trials (104,176 participants), standard-dose monotherapy reduced systolic BP by 8.7 mm Hg (each dose doubling added 1.5 mm Hg), while one-standard-dose dual combinations reduced systolic BP by 14.9 mm Hg (each doubling added 2.5 mm Hg). Efficacy decreased with lower baseline BP, and a validated model accurately predicted combination effects, enabling therapy to be classified into low, moderate, and high intensity.
Impact: Provides robust, generalizable dose–response and combination-effect estimates with a validated predictive model, directly informing rational antihypertensive regimen selection.
Clinical Implications: Use intensity-based targets to select single or dual agents and titrate doses to achieve desired mm Hg reductions; anticipate smaller effects in lower baseline BP; employ the model to design efficient stepwise combination therapy.
Key Findings
- Standard-dose monotherapy reduced systolic BP by 8.7 mm Hg; each dose doubling added 1.5 mm Hg.
- One-standard-dose dual combinations reduced systolic BP by 14.9 mm Hg; doubling both doses added 2.5 mm Hg.
- Lower baseline systolic BP reduced observed treatment efficacy by 1.3 mm Hg per 10 mm Hg decrease.
- Predictive model for combinations showed strong external validation (r=0.76).
Methodological Strengths
- Large-scale synthesis of 484 randomized, double-blind, placebo-controlled trials
- Pre-registered protocol with external validation of a predictive efficacy model
Limitations
- Short follow-up durations (mean 8.6 weeks) limit long-term extrapolation
- Fixed-effects approach and between-trial heterogeneity may influence pooled estimates; safety outcomes not primary focus
Future Directions: Incorporate long-term outcomes, adverse effects, and diverse populations to refine intensity-based treatment algorithms and integrate into decision-support tools.
BACKGROUND: We aimed to quantify the blood pressure-lowering efficacy of antihypertensive drugs and their combinations from the five major drug classes. METHODS: We conducted a systematic review and meta-analysis of randomised, double-blind, placebo-controlled trials involving adult participants randomly assigned to receive angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers, β blockers, calcium channel blockers, or diuretics. Eligibility criteria included follow-up duration betw
2. Physiology-Guided Complete Revascularization in Older Patients With Myocardial Infarction: Three-Year Outcomes of a Randomized Clinical Trial.
In 1,445 patients ≥75 years with MI and multivessel disease, physiology-guided complete revascularization reduced the 3-year composite of death/MI/stroke/ischemia-driven revascularization (HR 0.72) versus culprit-only treatment. Cardiovascular death or MI (HR 0.66) and heart failure hospitalizations (HR 0.73) were also significantly lower.
Impact: Confirms durability of benefits for complete, physiology-guided PCI in older MI patients over 3 years, informing guideline and heart-team decisions for a high-risk population.
Clinical Implications: Support complete, physiology-guided revascularization rather than culprit-only PCI in older MI patients with multivessel disease to reduce recurrent ischemic events and heart failure admissions.
Key Findings
- Primary composite endpoint at 3 years: 22.9% vs 29.8% (HR 0.72, 95% CI 0.58–0.88).
- Cardiovascular death or MI reduced (12.8% vs 18.2%; HR 0.66, 95% CI 0.50–0.88).
- Heart failure hospitalizations lower with complete revascularization (14.3% vs 19.7%; HR 0.73, 95% CI 0.54–0.97).
Methodological Strengths
- Multicenter randomized design with elderly population and 3-year follow-up
- Physiology-guided strategy with clinically meaningful endpoints
Limitations
- Open-label design may influence downstream management decisions
- Generalizability limited to patients ≥75 years; certain lesion subsets excluded
Future Directions: Assess cost-effectiveness, frailty subgroups, and optimal timing/extent of nonculprit lesion treatment in elderly patients.
IMPORTANCE: Complete revascularization in older patients with myocardial infarction (MI) and multivessel disease has been shown to reduce cardiovascular death and MI at 1 year. However, the durability of this benefit over longer follow-up periods has been questioned by recent studies. OBJECTIVE: To determine whether the benefit of physiology-guided complete treatment, compared with culprit-only treatment, is sustained at 3 years in older patients with MI and multivessel disease. DESIGN, SETTING, AND PA
3. Computed Tomography Angiography or Standard Care After Left Main PCI?
In 606 patients post–left main PCI, routine 6-month CCTA did not reduce the 18-month composite of death, spontaneous MI, unstable angina, or stent thrombosis (11.9% vs 12.5%; HR 0.97). CCTA reduced spontaneous MI (0.9% vs 4.9%) but increased imaging-triggered TLR (4.9% vs 0.3%), with similar clinically driven TLR rates.
Impact: Provides randomized evidence on a common surveillance strategy after complex LM PCI, clarifying benefits (fewer spontaneous MIs) and trade-offs (more imaging-triggered revascularization).
Clinical Implications: Routine CCTA may be considered selectively after LM PCI, balancing a reduction in spontaneous MI against increased imaging-driven interventions; clinical symptoms/ischemia-guided strategies remain reasonable.
Key Findings
- Primary composite endpoint at 18 months was similar (11.9% vs 12.5%; HR 0.97; P=0.80).
- Spontaneous MI was reduced in the CCTA arm (0.9% vs 4.9%; HR 0.26; P=0.004).
- Imaging-triggered TLR increased with CCTA (4.9% vs 0.3%; HR 7.7; P=0.001), while clinically driven TLR was similar (5.3% vs 7.2%; P=0.32).
Methodological Strengths
- Prospective multicenter randomized design in a high-risk LM PCI population
- High CCTA adherence (≈90%) with prespecified clinical endpoints
Limitations
- Open-label design; neutral primary endpoint may limit routine adoption
- Follow-up limited to 18 months; radiation exposure and cost-effectiveness not fully assessed
Future Directions: Identify anatomical/clinical subgroups deriving net benefit from surveillance CCTA and evaluate cost-effectiveness and radiation-sparing protocols.
BACKGROUND: The clinical benefit of routine coronary computed tomography angiography (CCTA) after percutaneous coronary intervention (PCI) for unprotected left main (LM) disease is uncertain. OBJECTIVES: The authors evaluated whether CCTA-guided follow-up improves clinical outcomes vs symptoms- or ischemia-driven care after LM PCI. METHODS: PULSE was a prospective, multicenter, open-label randomized trial. A total of 606 patients treated with second-generation drug-eluting stents were enrolled (October 2019